Metraipolis › archive › dc_a6688052ab79
AZD-7268 — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/AZD-7268
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-07T01:24:49.374Z
- SHA-256 of the archived text
c0898d278d784697ed53ee9f35b9d26689cde855e348cf10894efc4125faeaa0- Stable URL of this page
https://metraipolis.com/documento/dc_a6688052ab79
How to cite
AZD-7268 — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/AZD-7268 (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_a6688052ab79 (Metraipolis archive dc_a6688052ab79, sha256 c0898d278d784697ed53ee9f35b9d26689cde855e348cf10894efc4125faeaa0)
BibTeX
@misc{dca6688052ab79,
title = {AZD-7268 — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/AZD-7268},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_a6688052ab79; sha256 c0898d278d784697ed53ee9f35b9d26689cde855e348cf10894efc4125faeaa0},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/AZD-7268. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
AZD-7268 is a δ-opioid receptor agonist which was under development for the treatment of major depressive disorder but was never marketed. It is taken by mouth. The affinity (Ki) of AZD-7268 for the δ-opioid receptor was reported to be 2.7 nM and its selectivity for this receptor over the μ-opioid receptor was reported to be 2,000-fold. No animal studies of AZD-7268 appear to have been published. In addition to putative antidepressant effects, AZD-7268 might have anxiolytic effects. Structurally, AZD-7268 was derived from SNC-80. Dose-limiting side effects of AZD-7268 in clinical trials included syncope (fainting), hypotension (low blood pressure), and dizziness. AZD-7268 was first described by 2007. Its development was discontinued in 2010. It reached phase 2 clinical trials prior to the discontinuation of its development. No reason was given for the discontinuation of its development. However, the drug was found to be ineffective for major depressive disorder in a phase 2 clinical trial of 231 participants comparing it with placebo and escitalopram. The drug was under development by AstraZeneca. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «AZD-7268» — https://en.wikipedia.org/wiki/AZD-7268 Wikidata Q27074783: «composto chimico» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q27074783 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/AZD-7268?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1384045322, consultata il 2026-11-07T01:21:15.859Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 0609e588caba838425beb8b77441f768fed77fb110a83a33e59e979b58c2ce8d